Loading…

Loading grant details…

Active HORIZON European Commission

Dissecting the Functional Role of Mucosal IgA Clonal and Glycoprofiles for Effective Humoral Mucosal Protection

€1.49M EUR

Funder European Commission
Recipient Organization Karolinska Institutet
Country Sweden
Start Date Jan 01, 2025
End Date Dec 31, 2029
Duration 1,825 days
Number of Grantees 4
Roles Participant; Coordinator
Data Source European Commission
Grant ID 101164772
Grant Description

Numerous mucosal vaccines and IgA-based monoclonal antibodies aimed at a robust immunity within the respiratory tract are in development to combat viral endemics and pandemics.

However, investigations into humoral immunity have predominantly focused on circulating antibodies, particularly those of the IgG isotype.

This has left a significant void in our understanding of the role of mucosal IgA proteoforms in conveying effective immune protection.

This crucial knowledge gap deprives vaccine and antibody development of crucial determinants or immune characteristics to replicate.In response to this, we will conduct in-depth investigations of mucosal IgA including in vitro and in vivo functional evaluations.

We will capitalize on recent advances in liquid chromatography and mass spectrometry-based approaches for the detailed characterization of mucosal IgA clonal repertoires and glycosylation profiles, a field that has remained completely unexplored until now, B-cell receptor sequencing, monoclonal IgA glycoengineering and in vitro functional assays.

We will take advantage of our unparalleled biobank of human nasal secretion samples with clear documentations of infection outcomes on an individual level.

What sets our approach apart is thereby the unprecedented molecular-level characterization of IgA, directly linked to their in vitro functionality and pre-defined clinical outcomes, which clearly surpasses current state-of-the-art.By harnessing our in-depth characterization of mucosal IgA coupled to functional traits, we will generate IgA templates with enhanced binding and neutralization capabilities as well as functionally advantageous Fc effector potencies.

Our overarching aim is to provide molecular-level blueprints for protective monoclonal IgA-antibodies, enabling the fine-tuning of vaccine formulations and monoclonal antibody generation with a higher degree of accuracy, ultimately enhancing their efficacy and safety.

All Grantees

Academisch Ziekenhuis Leiden; Danderyds Sjukus Aktiebolag; Stichting Sanquin Bloedvoorziening; Karolinska Institutet

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant